Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Patients with CD30 positive DLBCL, primary refractory or in first relapse after R-CHOP or R-CHOP-like therapy will receive brentuximab vedotin in combination with R-DHAP, followed in responsive patients by high dose chemotherapy and ASCT.

Trial Details

NCT ID
NCT03356054
Phase
PHASE1 / PHASE2
Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • R-DHAP
  • Brentuximab Vedotin
Locations (sample)
  • Rotterdam, Netherlands|51.9225,4.47917

Key Eligibility Criteria

  • CD30 positive DLBCL, i.e. more than 1% of DLBCL cells CD30 positive(central pathology review results not required to enter patient into the study),…
  • CD30 positive DLBCL, including EBV positive DLBCL
  • CD30 positive primary mediastinal B-cell lymphoma
  • Primary refractory to or in first relapse after first line therapy with R-CHOP or R-CHOP-like therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →